<div class="floatDisplay"><div class="table-wrap" id="tbl2">
<table>
<caption tabindex="0">
<span class="label">Table 2</span><span>Statistical analysis of change from baseline in WPAI: asthma-derived scores (Week 52 data).<a href="#title-footnote-tbl2fna" id="back-title-footnote-tbl2fna" class="figureLink"><sup>a</sup></a><span class="crossref-label" style="display: none;"></span></span>
</caption>
<tbody>
<tr>
<th scope="col" rowspan="3"></th>
<th scope="col" colspan="3">Overall study population</th>
<th scope="col" colspan="3">ICS subset</th>
<th scope="col" colspan="3">ICS/LABA subset</th>
</tr>
<tr>
<th scope="col" colspan="2">LS mean change from baseline (SE), %</th>
<th scope="col" rowspan="2">Difference FF/VI <em>versus</em> UC, %<br><br>(95% CI)<a href="#title-footnote-tbl2fnb" id="back-title-footnote-tbl2fnb" class="figureLink"><sup>b</sup></a><span class="crossref-label" style="display: none;"></span><br><br>p-value</th>
<th scope="col" colspan="2">LS mean change from baseline (SE), %</th>
<th scope="col" rowspan="2">Difference FF/VI <em>versus</em> UC, %<br><br>(95% CI)<a href="#title-footnote-tbl2fnc" id="back-title-footnote-tbl2fnc" class="figureLink"><sup>c</sup></a><span class="crossref-label" style="display: none;"></span><br><br>p-value</th>
<th scope="col" colspan="2">LS mean change from baseline (SE), %</th>
<th scope="col" rowspan="2">Difference FF/VI v<em>ersus</em> UC, %<br><br>(95% CI)<a href="#title-footnote-tbl2fnc" id="back-title-footnote-tbl2fnc" class="figureLink"><sup>c</sup></a><span class="crossref-label" style="display: none;"></span><br><br>p-value</th>
</tr>
<tr>
<th scope="col">FF/VI (n = 2114)</th>
<th scope="col">UC (n = 2119)</th>
<th scope="col">FF/VI (n = 750)</th>
<th scope="col">UC (n = 755)</th>
<th scope="col">FF/VI (n = 1325)</th>
<th scope="col">UC (n = 1325)</th>
</tr>
<tr>
<th scope="row">Percent work time missed due to asthma</th>
<td>n = 833<br><br>−0.3 (0.38)</td>
<td>n = 835<br><br>0.3 (0.37)</td>
<td>−0.6 (−1.7 to 0.4)<br><br><em>p</em> = .223</td>
<td>n = 311<br><br>−0.0 (0.62)</td>
<td>n = 338<br><br>0.4 (0.59)</td>
<td>−0.4 (−2.0 to 1.3)<br><br><em>p</em> = .650</td>
<td>n = 508<br><br>−0.6 (0.45)</td>
<td>n = 484<br><br>−0.1 (0.47)</td>
<td>−0.5 (−1.8 to 0.8)<br><br><em>p</em> = .440</td>
</tr>
<tr>
<th scope="row">Percent impairment while working due to asthma</th>
<td>n = 823<br><br>−6.9 (0.56)</td>
<td>n = 822<br><br>−4.1 (0.55)</td>
<td>−2.8 (−4.3 to −1.3)<br><br><em>p</em> &lt; .001</td>
<td>n = 305<br><br>−5.7 (0.81)</td>
<td>n = 335<br><br>−2.9 (0.77)</td>
<td>−2.8 (−5.0 to −0.6)<br><br><em>p</em> = .011</td>
<td>n = 503<br><br>−7.4 (0.75)</td>
<td>n = 476<br><br>−4.5 (0.78)</td>
<td>−2.9 (−5.0 to −0.8)<br><br><em>p</em> = .007</td>
</tr>
<tr>
<th scope="row">Percent overall work impairment due to asthma</th>
<td>n = 822<br><br>−6.7 (0.60)</td>
<td>n = 823<br><br>−4.0 (0.59)</td>
<td>−2.8 (−4.4 to −1.1)<br><br><em>p</em> &lt; .001</td>
<td>n = 305<br><br>−5.6 (0.88)</td>
<td>n = 335<br><br>−2.8 (0.84)</td>
<td>−2.9 (−5.2 to −0.5)<br><br><em>p</em> = .018</td>
<td>n = 503<br><br>−7.1 (0.80)</td>
<td>n = 476<br><br>−4.4 (0.83)</td>
<td>−2.7 (−5.0 to −0.4)<br><br><em>p</em> = .019</td>
</tr>
<tr>
<th scope="row">Percent activity impairment due to asthma</th>
<td>n = 1982<br><br>−10.4 (0.50)</td>
<td>n = 1987<br><br>−5.9 (0.50)</td>
<td>−4.5 (−5.9 to −3.2)<br><br><em>p</em> &lt; .001</td>
<td>n = 696<br><br>−8.5 (0.77)</td>
<td>n = 710<br><br>−4.1 (0.76)</td>
<td>−4.4 (−6.5 to −2.3)<br><br><em>p</em> &lt; .001</td>
<td>n = 1250<br><br>−10.8 (0.65)</td>
<td>n = 1243<br><br>−6.0 (0.66)</td>
<td>−4.8 (−6.6 to −3.0)<br><br><em>p</em> &lt; .001</td>
</tr>
</tbody>
</table>
<a href="javascript:void(0)" class="tableLink" onclick="window.open('/action/showFullTableImage?isHtml=true&amp;tableId=tbl2&amp;pii=S095461111830194X', '_blank')">
                        View Table in HTML
                    </a><div class="footnote"><p>Abbreviations: ANCOVA, 
analysis of covariance; CI, confidence interval; FF/VI, fluticasone 
furoate/vilanterol; ICS, inhaled corticosteroid; LABA, long-acting beta<sub>2</sub>-agonist; LS, least squares; SE, standard error; UC, usual care; WPAI, work productivity and activity impairment.</p></div>
<div class="footnote" id="tbl2fna">
<a href="#back-tbl2fna">a</a>Data based on last available on-treatment measurement (Week 52 or early withdrawal visit).</div>
<div class="footnote" id="tbl2fnb">
<a href="#back-tbl2fnb">b</a>Between-group differences (FF/VI <em>versus</em>
 UC), 95% CIs, and associated p-values were calculated using an ANCOVA 
model adjusted for randomized treatment, asthma maintenance therapy at 
baseline per randomization stratification, ACT total score at baseline 
per randomization stratification, gender, age, and baseline WPAI score.</div>
<div class="footnote" id="tbl2fnc">
<a href="#back-tbl2fnc">c</a>For
 analysis of the ICS and ICS/LABA subsets of the overall study 
population, the statistical models did not include the asthma 
maintenance therapy at baseline per randomization stratification 
variable.</div>
</div></div>